tiprankstipranks
Advertisement
Advertisement
Early Phase Data for STORM Therapeutics’ METTL3 Inhibitor Signals Potential in Sarcoma
PremiumPrivate CompaniesEarly Phase Data for STORM Therapeutics’ METTL3 Inhibitor Signals Potential in Sarcoma
1M ago
Early-Stage Sarcoma Data Highlight Potential of STORM Therapeutics’ METTL3 Inhibitor
Premium
Private Companies
Early-Stage Sarcoma Data Highlight Potential of STORM Therapeutics’ METTL3 Inhibitor
1M ago
M Ventures – Weekly Recap
Premium
Private Companies
M Ventures – Weekly Recap
1M ago
Theolytics Advances THEO-260 Into U.S. Phase 1 Trial for Resistant Ovarian Cancer
PremiumPrivate CompaniesTheolytics Advances THEO-260 Into U.S. Phase 1 Trial for Resistant Ovarian Cancer
2M ago
Theolytics Advances THEO-260 Into Second Clinical Trial for Platinum-Resistant Ovarian Cancer
Premium
Private Companies
Theolytics Advances THEO-260 Into Second Clinical Trial for Platinum-Resistant Ovarian Cancer
2M ago
M Ventures – Weekly Recap
Premium
Private Companies
M Ventures – Weekly Recap
2M ago
M Ventures Highlights Focus on Bio–Semiconductor Convergence at Bioconvergence Conference
PremiumPrivate CompaniesM Ventures Highlights Focus on Bio–Semiconductor Convergence at Bioconvergence Conference
3M ago
M Ventures Highlights Focus on Bioconvergence and Tech-Enabled Bio Investing
Premium
Private Companies
M Ventures Highlights Focus on Bioconvergence and Tech-Enabled Bio Investing
3M ago
M Ventures Strengthens Tech Investment Team With AI-Focused Director Hire
Premium
Private Companies
M Ventures Strengthens Tech Investment Team With AI-Focused Director Hire
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100